Consistent with the results from mouse studies, we showed that glioma-CM-pretreated human ECs stimulated human monocytes toward alternative activation, as evidenced by increased CD206+CD86+ populations in CD11b+ cells (Fig. 2c). This evidence concerns the gene MRC1 and central nervous system cancer.